Moleculin Biotech Inc
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered sales of Equity Securities and Uses of Proceeds
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
During the three months ended March 31, 2024, the Company issued warrants to purchase 3,334 shares of common stock with an exercise price of $9.15 per share to an entity providing consulting services, which warrants will vest annually over four years while services are being performed. The foregoing securities were issued pursuant to Section 4(a)(2) of the Securities Act.
During the three months ended March 31, 2024, the Company issued 6,834 shares of common stock to consultants in exchange for services to be provided. The foregoing securities were issued pursuant to Section 4(a)(2) of the Securities Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.